194 related articles for article (PubMed ID: 30115695)
1. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Eleveld TF; Schild L; Koster J; Zwijnenburg DA; Alles LK; Ebus ME; Volckmann R; Tijtgat GA; van Sluis P; Versteeg R; Molenaar JJ
Cancer Res; 2018 Nov; 78(21):6297-6307. PubMed ID: 30115695
[TBL] [Abstract][Full Text] [Related]
2.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
3. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
[TBL] [Abstract][Full Text] [Related]
4. The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation.
Weissmann S; Cloos PA; Sidoli S; Jensen ON; Pollard S; Helin K
Cancer Res; 2018 Aug; 78(15):4114-4125. PubMed ID: 29844126
[TBL] [Abstract][Full Text] [Related]
5. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
Mus LM; Lambertz I; Claeys S; Kumps C; Van Loocke W; Van Neste C; Umapathy G; Vaapil M; Bartenhagen C; Laureys G; De Wever O; Bexell D; Fischer M; Hallberg B; Schulte J; De Wilde B; Durinck K; Denecker G; De Preter K; Speleman F
Sci Rep; 2020 Jan; 10(1):218. PubMed ID: 31937834
[TBL] [Abstract][Full Text] [Related]
6. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
7. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
9. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
10. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma.
Simón-Carrasco L; Graña O; Salmón M; Jacob HKC; Gutierrez A; Jiménez G; Drosten M; Barbacid M
Genes Dev; 2017 Jul; 31(14):1456-1468. PubMed ID: 28827401
[TBL] [Abstract][Full Text] [Related]
12. ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.
Wang B; Krall EB; Aguirre AJ; Kim M; Widlund HR; Doshi MB; Sicinska E; Sulahian R; Goodale A; Cowley GS; Piccioni F; Doench JG; Root DE; Hahn WC
Cell Rep; 2017 Feb; 18(6):1543-1557. PubMed ID: 28178529
[TBL] [Abstract][Full Text] [Related]
13. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
[TBL] [Abstract][Full Text] [Related]
14. Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade.
LeBlanc VG; Firme M; Song J; Chan SY; Lee MH; Yip S; Chittaranjan S; Marra MA
J Pathol; 2017 Jun; 242(2):206-220. PubMed ID: 28295365
[TBL] [Abstract][Full Text] [Related]
15. The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer.
Simón-Carrasco L; Jiménez G; Barbacid M; Drosten M
Cell Cycle; 2018; 17(6):702-711. PubMed ID: 29578365
[TBL] [Abstract][Full Text] [Related]
16. Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells.
Espino PS; Pritchard S; Heng HH; Davie JR
Int J Cancer; 2009 Feb; 124(3):562-7. PubMed ID: 19004007
[TBL] [Abstract][Full Text] [Related]
17. CIC protein instability contributes to tumorigenesis in glioblastoma.
Bunda S; Heir P; Metcalf J; Li ASC; Agnihotri S; Pusch S; Yasin M; Li M; Burrell K; Mansouri S; Singh O; Wilson M; Alamsahebpour A; Nejad R; Choi B; Kim D; von Deimling A; Zadeh G; Aldape K
Nat Commun; 2019 Feb; 10(1):661. PubMed ID: 30737375
[TBL] [Abstract][Full Text] [Related]
18. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action.
Masliah-Planchon J; Garinet S; Pasmant E
Oncotarget; 2016 Jun; 7(25):38892-38907. PubMed ID: 26646588
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.
Hart LS; Rader J; Raman P; Batra V; Russell MR; Tsang M; Gagliardi M; Chen L; Martinez D; Li Y; Wood A; Kim S; Parasuraman S; Delach S; Cole KA; Krupa S; Boehm M; Peters M; Caponigro G; Maris JM
Clin Cancer Res; 2017 Apr; 23(7):1785-1796. PubMed ID: 27729458
[No Abstract] [Full Text] [Related]
20. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
